진행성 고형 종양의 SW-682
Hippo 경로 돌연변이가 있는 환자를 위해 강화된 진행성 고형 종양 환자를 대상으로 SW-682의 1a/1b상 용량 증량, 용량 확장 연구
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: US Medical Information
- 전화번호: 888-275-7376
- 이메일: eMediUSA@emdserono.com
연구 장소
-
-
Arizona
-
Scottsdale, Arizona, 미국, 85258
- 모병
- HonorHealth Research Institute
-
수석 연구원:
- Muhammad R Khawaja, MD
-
연락하다:
-
-
California
-
Los Angeles, California, 미국, 90033
- 모병
- USC Norris Comprehensive Cancer Center and Hospital
-
수석 연구원:
- Diana Hanna, MD
-
연락하다:
-
Sacramento, California, 미국, 92093
- 모병
- UC San Diego Moores Cancer Center
-
수석 연구원:
- Sandip Patel, MD
-
연락하다:
- 이메일: sandippatel@ucsd.edu
-
Santa Monica, California, 미국, 90404
- 모병
- UCLA Hematology-Oncology - Santa Monica
-
수석 연구원:
- Arun S Singh, MD
-
연락하다:
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- 모병
- University Hospital of Cleveland
-
수석 연구원:
- Afshin Dowlati, MD
-
연락하다:
- 전화번호: 216-844-3951
- 이메일: afshin.dowlati@uhhospitals.org
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 모병
- Oregon Health and Science University, Knight Cancer Institute - Marquam Hill
-
수석 연구원:
- Shivaani Kummar
-
연락하다:
- 이메일: kummar@ohsu.edu
-
-
Texas
-
Dallas, Texas, 미국, 75230
- 모병
- Mary Crowley Research Center US Oncology
-
수석 연구원:
- Douglas Orr, MD
-
연락하다:
- 전화번호: 972-566-3000
- 이메일: Douglas.Orr@scri.com
-
Houston, Texas, 미국, 77030
- 모병
- U.T. MD Anderson Cancer Center
-
수석 연구원:
- Timothy Yap, MD
-
연락하다:
- 이메일: TYap@mdanderson.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
-
Histologically confirmed, metastatic, or unresectable solid cancer that has either not responded to or progressed during or after appropriate prior systemic anticancer therapy including chemotherapy, immunotherapy, radiation therapy, or appropriate targeted therapy, or for which there is no treatment available or prior SOC therapy was not tolerated and for which there is no further SOC treatment available
-
Part 1: must have one of the following:
- Mesothelioma with or without NF2 mutations
- Advanced solid tumors with NF2 mutations
- Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE).
-
Part 2: must have the tumor histology and oncogenic mutation or genomic aberration specific to each dose expansion cohort defined below:
- Cohort 1: Participants with mesothelioma with or without NF2 mutations
- Cohort 2: Participants with advanced solid tumors with NF2 mutations
- Cohort 3: Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation
- Cohort 4: SW-682 with appropriate combination therapy.
-
In both parts, participants should have known oncogenic mutation identified by Next Generation Sequencing or local assay
-
Must have archival tumor tissue or agree to a fresh tumor biopsy at screening
-
Measurable disease per RECIST 1.1
-
Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
-
Adequate bone marrow, kidney, hepatic, and coagulation function
Key Exclusion Criteria:
- Evidence of symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression
- Clinically significant cardiac disease or abnormal cardiac parameters
- Preexistence or inheritance of a familial renal syndrome
- Concomitant non-anti-arrhythmic medications that are known to prolong the QTc interval
- Concomitant medicines that are known strong/moderate inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and/or CYP1A2 within 14 days or 5 half-lives before the first dose of study treatment
- Concomitant medicines that are known sensitive substrates of CYP3A4, CYP2C19, CYP2D6, CYP1A2, and/or CYP2B6 within 14 days or 5 half-lives before the first dose of study treatment
- Concomitant medicines that are known sensitive substrates of PGP, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, OCT2
- Clinically significant active infection (bacterial, fungal, or viral)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Phase 1 Dose Escalation Cohorts Ranging in Dose
Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort. |
SW-682 tablet administered orally |
|
실험적: Part 2 Dose Expansion Cohort 1
Participants with mesothelioma with or without NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
실험적: Part 2 Dose Expansion Cohort 2
Participants with advanced solid tumors with NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
실험적: Part 2 Dose Expansion Cohort 3
Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
실험적: Part 2 Dose Expansion Cohort 4
Participants will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data, with appropriate combination therapy, identified based on Part 1 data. |
SW-682 tablet administered orally Appropriate combination therapy |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Adverse Events (Part 1 Only)
기간: Up to 24 months
|
Safety and tolerability endpoint evaluation via incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment emergent adverse events (TEAE) |
Up to 24 months
|
|
Maximum Tolerated Dose (Part 1 Only)
기간: Up to 24 months
|
The maximum tolerated dose (MTD) for SW-682, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1. |
Up to 24 months
|
|
Recommended Dose for Expansion (Part 1 Only)
기간: Up to 24 months
|
The recommended dose for expansion (RDE) will be determined based on all safety, tolerability, pharmacokinetics (PK), preliminary antitumor efficacy, and other available data from Part 1 of the study. |
Up to 24 months
|
|
Objective Response Rate (Part 2 Only)
기간: Up to 24 months
|
Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator. |
Up to 24 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in plasma and urine concentrations of SW-682
기간: Up to 24 months
|
Plasma and urine concentrations of SW-682 and any relevant metabolite(s) will be measured to evaluate systemic exposures and renal elimination. |
Up to 24 months
|
|
Objective Response Rate (Part 1 Only)
기간: Up to 24 months
|
Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator. |
Up to 24 months
|
|
Disease Control Rate
기간: Up to 24 months
|
Disease control rate (DCR), defined as the percentage of participants with CR, PR, or stable disease (SD) after starting study treatment. |
Up to 24 months
|
|
Duration of Response
기간: Up to 24 months
|
Duration of response (DoR), defined as the time from response (CR + PR using RECIST v1.1, mRECIST and/or (GCIG) criteria for CA-125 response in ovarian cancer, as applicable) to disease progression and/or death, whichever occurs first. |
Up to 24 months
|
|
Progression-Free Survival
기간: Up to 24 months
|
Progression-free survival (PFS), defined as the time from the date of the first administration of study treatment to the first documented disease progression per RECIST v1.1, mRECIST, and/or GCIG CA-125, as applicable, or death due to any cause, whichever occurs first. |
Up to 24 months
|
공동 작업자 및 조사자
스폰서
스폰서
수사관
수사관
- 연구 책임자: Medical Responsible, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- TEAD-AST-101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .